These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 30651929)

  • 1. Insight into the PTEN - p85α interaction and lipid binding properties of the p85α BH domain.
    Marshall JDS; Mellor P; Ruan X; Whitecross DE; Moore SA; Anderson DH
    Oncotarget; 2018 Dec; 9(97):36975-36992. PubMed ID: 30651929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the PI3K pathway through a p85α monomer-homodimer equilibrium.
    Cheung LW; Walkiewicz KW; Besong TM; Guo H; Hawke DH; Arold ST; Mills GB
    Elife; 2015 Jul; 4():e06866. PubMed ID: 26222500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived mutations within the N-terminal domains of p85α impact PTEN or Rab5 binding and regulation.
    Mellor P; Marshall JDS; Ruan X; Whitecross DE; Ross RL; Knowles MA; Moore SA; Anderson DH
    Sci Rep; 2018 May; 8(1):7108. PubMed ID: 29740032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of p85α Alterations in Cancer.
    Marshall JDS; Whitecross DE; Mellor P; Anderson DH
    Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30650664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase.
    Chagpar RB; Links PH; Pastor MC; Furber LA; Hawrysh AD; Chamberlain MD; Anderson DH
    Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5471-6. PubMed ID: 20212113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The SH3 and BH domains of the p85alpha adapter subunit play a critical role in regulating class Ia phosphoinositide 3-kinase function.
    Beeton CA; Das P; Waterfield MD; Shepherd PR
    Mol Cell Biol Res Commun; 1999 May; 1(2):153-7. PubMed ID: 10356365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple roles for the p85α isoform in the regulation and function of PI3K signalling and receptor trafficking.
    Mellor P; Furber LA; Nyarko JN; Anderson DH
    Biochem J; 2012 Jan; 441(1):23-37. PubMed ID: 22168437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of mutations in distinct regions of p85 alpha in urothelial cancer.
    Ross RL; Burns JE; Taylor CF; Mellor P; Anderson DH; Knowles MA
    PLoS One; 2013; 8(12):e84411. PubMed ID: 24367658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of phospho-p85α-GTP-Rac1 lipid raft interaction by bichalcone analog attenuates cancer cell invasion.
    Lu HL; Chen SS; Hsu WT; Lu YC; Lee CC; Wu TS; Lin ML
    Mol Carcinog; 2016 Dec; 55(12):2106-2120. PubMed ID: 26756739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into the pathological mechanisms of p85α mutations using a yeast-based phosphatidylinositol 3-kinase model.
    Oliver MD; Fernández-Acero T; Luna S; Rodríguez-Escudero I; Molina M; Pulido R; Cid VJ
    Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28143957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α.
    Echeverria I; Liu Y; Gabelli SB; Amzel LM
    FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted molecular therapy of the PI3K pathway: therapeutic significance of PI3K subunit targeting in colorectal carcinoma.
    Rychahou PG; Jackson LN; Silva SR; Rajaraman S; Evers BM
    Ann Surg; 2006 Jun; 243(6):833-42; discussion 843-4. PubMed ID: 16772787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
    Luo J; Sobkiw CL; Logsdon NM; Watt JM; Signoretti S; O'Connell F; Shin E; Shim Y; Pao L; Neel BG; Depinho RA; Loda M; Cantley LC
    Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10238-43. PubMed ID: 16006513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Backbone dynamics of the C-terminal SH2 domain of the p85alpha subunit of phosphoinositide 3-kinase: effect of phosphotyrosine-peptide binding and characterization of slow conformational exchange processes.
    Kristensen SM; Siegal G; Sankar A; Driscoll PC
    J Mol Biol; 2000 Jun; 299(3):771-88. PubMed ID: 10835283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The WW domain of IQGAP1 binds directly to the p110α catalytic subunit of PI 3-kinase.
    Bardwell AJ; Paul M; Yoneda KC; Andrade-Ludeña MD; Nguyen OT; Fruman D; Bardwell L
    Biochem J; 2023 May; ():. PubMed ID: 37145016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galphaq binds to p110alpha/p85alpha phosphoinositide 3-kinase and displaces Ras.
    Ballou LM; Chattopadhyay M; Li Y; Scarlata S; Lin RZ
    Biochem J; 2006 Mar; 394(Pt 3):557-62. PubMed ID: 16268778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cloning, expression, purification, and characterization of the human Class Ia phosphoinositide 3-kinase isoforms.
    Meier TI; Cook JA; Thomas JE; Radding JA; Horn C; Lingaraj T; Smith MC
    Protein Expr Purif; 2004 Jun; 35(2):218-24. PubMed ID: 15135396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.
    Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM
    Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of PI3K/Akt signaling by n-terminal SH2 domain mutants of the p85α regulatory subunit of PI3K is enhanced by deletion of its c-terminal SH2 domain.
    Hofmann BT; Jücker M
    Cell Signal; 2012 Oct; 24(10):1950-4. PubMed ID: 22735814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Domain analysis reveals striking functional differences between the regulatory subunits of phosphatidylinositol 3-kinase (PI3K), p85α and p85β.
    Ito Y; Vogt PK; Hart JR
    Oncotarget; 2017 Aug; 8(34):55863-55876. PubMed ID: 28915558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.